Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray

Blood

Volumn 98, Issue 3, 2001, Pages 787-794

  Hofmann, Wolf K ^a,b,c,d   De Vos, Sven ^a,b,c,d   Tsukasaki, Kunihiro ^a,b,c,d   Wachsman, William ^a,b,c,d   Pinkus, Geraldine S ^a,b,c,d   Said, Jonathan W ^a,b,c,d   Phillip Koeffler, H ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VASDHS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; CASPASE 2; CYCLIN D1; DAXX PROTEIN; GENE PRODUCT; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CASP2 GENE; CELL CYCLE; CELL SURVIVAL; COMPUTER PROGRAM; DAXX GENE; DNA MICROARRAY; FADD GENE; GENE EXPRESSION REGULATION; GENE ISOLATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC SELECTION; HUMAN; LYMPH NODE HYPERPLASIA; LYMPHOMA; MANTLE CELL LYMPHOMA; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RAIDD GENE; RNA ANALYSIS; UNINDEXED SEQUENCE;

EID: 0035437143     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.3.787     Document Type: Article

References (49)

1. Zucca E, Stein H, Coiffier B. European Lymphoma Task Force (ELTF): report of the workshop on mantle cell lymphoma (MCL). Ann Oncol. 1999;5:507-511.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
3. Rosenberg CL, Wong E, Petty EM, et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A. 1991;88:9638-9642.
4. Bosch F, Jares P, Campo E, etal. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood. 1994;84:2726-2732.
5. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood. 1995;86:841-854.
6. Oka K, Ohno T, Kita K, et al. PRAD1 gene overexpression in mantle-cell lymphoma but not in other low-grade B-cell lymphomas, including extranodal lymphoma. Br J Haematol. 1994;86:786-791.
7. Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993;8:2127-2133.
8. Jares P, Rey MJ, Fernandez PL, et al. Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status. J Pathol. 1997;182:160-166.
9. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A. 1994;91:709-713.
10. Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13:3487-3495.
11. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467-470.
12. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
13. Wellmann A, Thieblemont C, Pittaluga S, et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood. 2000;96:398-404.
14. Anbazhagan R, Tihan T, Bornman DM, et al. Classification of small cell lung cancer and pulmonary carcinoid by gene expression profiles. Cancer Res. 1999;59:5119-5122.
15. Khan J, Simon R, Bittner M, et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res. 1998;58:5009-5013.
16. Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson JRJ, Elkahloun AG. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res. 1999;59:5656-5661.
17. Nacht M, Ferguson AT, Zhang W, et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res. 1999;59:5464-5470.
18. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A. 1999;96:9212-9217.
19. Tamayo P, Slonim D, Mesirov J, et al. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A. 1999;96:2907-2912.
20. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531-537.
21. Puissant C, Houdebine LM. An improvement of the single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Biotechniques. 1990;8:148-149.
22. Voehringer DW, Hirschberg DL, Xiao J, et al. Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis. Proc Natl Acad Sci U S A. 2000;97:2680-2685.
23. Kaminski N, Allard JD, Pittet JF, et al. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci U S A. 2000;97:1778-1783.
24. Peters UR, Tschan MP, Kreuzer KA, et al. Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. Cancer Res. 1999;59:4233-4236.
25. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 2000;25:169-193.
26. Pinkus GS, Lones M, Shintaku IP, Said JW. Immunohistochemical detection of Epstein-Barr virus-encoded latent membrane protein in Reed-Sternberg cells and variants of Hodgkin's disease. Mod Pathol. 1994;7:454-461.
27. Ratech H. Molecular pathology of low grade malignant lymphomas. Med Oncol. 1995;12:167-176.
28. Warrington JA, Nair A, Mahadevappa M, Tsyganskaya M. Comparison of human adult and fetal expression and identification of 535 housekeeping/maintenance genes. Physiol Genomics. 2000;2:143-147.
29. Zhao R, Gish K, Murphy M, et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 2000;14:981-993.
30. Ott MM, Bartkova J, Bartek J, et al. Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. Blood. 1997;90:3154-3159.
31. Chang HY, Yang X, Baltimore D. Dissecting Fas signaling with an altered-specificity death-domain mutant: requirement of FADD binding for apoptosis but not Jun N-terminal kinase activation. Proc Natl Acad Sci U S A. 1999;96:1252-1256.
32. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med. 1999;190:1025-1032.
33. Yeh WC, Pompa JL, McCurrach ME, et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science. 1998;279:1954-1958.
34. Boone E, Vanden BT, Van LG, et al. Structure/function analysis of p55 tumor necrosis factor receptor and Fas-associated death domain: effect on necrosis in L929sA cells. J Biol Chem. 2000;275:37596-37603.
35. Komada Y, Inaba H, Zhou YW, et al. mRNA expression of Fas receptor (CD95)-associated proteins (Fas-associated phosphatase-1/FAP-1, Fas-associating protein with death domain/FADD, and receptor-interacting protein/RIP) in human leukaemia/lymphoma cell lines. Br J Haematol. 1997;99:325-330.
36. Lens SM, den Drijver BF, Potgens AJ, Tesselaar K, van Oers MH, van Lier RA. Dissection of pathways leading to antigen receptor-induced and Fas/CD95-induced apoptosis in human B cells. J Immunol. 1998;160:6083-6092.
37. Tepper CG, Seldin MF. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood. 1999;94:1727-1737.
38. Yang X, Khosravi-Far R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell. 1997;89:1067-1076.
39. Torii S, Egan DA, Evans RA, Reed JC. Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs). EMBO J. 1999;18:6037-6049.
40. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141-151.
41. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319-322.
42. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-1034.
43. Finger LR, Pu J, Wasserman R, et al. The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Gene. 1997;197:177-187.
44. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobuin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887-3895.
45. Duan H, Dixit VM. RAIDD is a new 'death' adaptor molecule. Nature. 1997;385:86-89.
46. Nature Genetics Supplement, vol 21, January 1999.
47. GenBank. National Center for Biotechnology Information Web site. Available at: http://www.ncbi.nim.nih.gov/. Accessed December 2000.
48. Online Mendelian Inheritance in Man (OMIM). National Center for Biotechnology Information Web site. Available at: http://www.ncbi.nlm.nih.gov/omim/. Accessed December 2000.
49. Primer 3. Available at: http://www.genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi. Accessed September 2000.